Frontiers in Psychiatry
July 21, 2026
Kenneth P. Finn, Robin Murray, Elizabeth Stuyt et al.
Cannabis is one of the most widely used psychoactive substances, with higher use rates in countries that have implemented policies to legalize medical or recreational use. Following the development of cannabis products with concentrations well above 10% THC (high potency, delta-9 tetrahydrocannabinol), the number of psychosis cases has also increased. Cannabis-attributable psychosis cases...
Translational Psychiatry
July 16, 2026
Celia Martín-Cuevas, Víctor Darío Ramos‐Herrero, Álvaro Flores‐Martínez et al.
Since the discovery of the first antipsychotic, pharmacological treatment of schizophrenia (SCZ) has primarily relied on dopamine D2 receptor antagonist. However, variability in treatment responses highlights the need for novel biomarkers and therapeutics targets. Here, we developed a dual-hit mouse model combining maternal immune activation (MIA) induced by polyinosinic-polycytidylic acid...
Sciences of Phytochemistry
July 12, 2026
Fakhray Rimi, Jannatul Fardous, Fahmida Zaman et al.
Medicinal plants have been used in traditional medicine to alleviate a range of neurological and psychological disorders. Numerous plant-derived phytochemicals are known to modulate central nervous system activity by interacting with neurotransmitters, receptors, and neurochemical pathways. This review provides a comprehensive overview of medicinal plants with psychoactive properties, their...
Biological Psychology
July 9, 2026
Nattanon Bunrodchu, Ekkasit Kumarnsit, Wan Khairunizam Wan Ahmad et al.
Long-term cannabis use can result in the development of cannabis use disorder (CUD) and dependence via the endocannabinoid system pathway. A brain network that has been consistently linked to various stages of addiction and various substances is the default mode network (DMN). By comparing EEG features between cannabis users and healthy participants, this study sought to identify EEG-based...
Biol Psychiatry
July 1, 2026
Dynamic Brain States With Cannabis Intoxication: Beyond "More Is Better" in Interpreting Brain Connectivity.
JME Practical Bioethics
July 1, 2026
Edward Jacobs, Edward Palmer, Celia J. A. Morgan
Some investigational compounds exist in both regulated clinical pipelines and unregulated street or online markets. Ketamine, psychedelics and cannabis are all under active clinical investigation while remaining accessible, in unregulated form, through illicit channels without clinician oversight. We propose the term parallel-access compounds for this category and argue that it deserves...
Journal of Drug Issues
July 1, 2026
Haley M Hummel, Alexia N Obrochta, David C. R. Kerr et al.
Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use...